Systemic anaplastic large‐cell lymphoma: Results from the non‐Hodgkin's lymphoma classification project
Open Access
- 29 May 2001
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 67 (3) , 172-178
- https://doi.org/10.1002/ajh.1102
Abstract
Anaplastic large‐cell lymphoma (ALCL) is a heterogeneous process that may have a T‐cell, B‐cell, or indeterminant (null) phenotype and which may or may not express the anaplastic lymphoma kinase (ALK) oncoprotein. Because the clinical significance of these variants of ALCL is unclear, we evaluated the cases of ALCL‐T/null and ALCL‐B identified in the Non‐Hodgkin's Lymphoma Classification Project. We evaluated 1,378 cases of non‐Hodgkin's lymphoma (NHL), and a consensus diagnosis of ALCL‐T/null was made in 33 patients (2.4%) with a diagnostic accuracy of 85%. Compared to 96 patients with other forms of peripheral T‐cell lymphoma (PTCL), those with ALCL‐T/null were significantly younger, less likely to have advanced‐stage disease or bone marrow involvement, more likely to have a low International Prognostic Index score, and had a significantly better survival. Among those with ALCL‐T/null, there were no significant differences in the clinical features or survival on the basis of ALK expression. A consensus diagnosis of ALCL‐B was made in 15 patients (1.1%), and the diagnostic accuracy was 67%. However, compared to 366 patients with other forms of diffuse large B‐cell lymphoma (DLBCL), those with ALCL‐B were no different with regard to clinical features or survival. We conclude that patients with ALCL‐T/null have favorable prognostic features and excellent survival and should be separated from those with other forms of PTCL for prognostic and therapeutic purposes. In contrast, patients with ALCL‐B appear to be similar to those with other forms of DLBCL. Am. J. Hematol. 67:172–178, 2001.Keywords
Funding Information
- U.S. Public Health Service, National Cancer Institute, Department of Health and Human Services (CA36727)
- Foundation San Salvatore
- Stacey Greene family
- Imperial Cancer Research Foundation, U.K.
This publication has 31 references indexed in Scilit:
- World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997Journal of Clinical Oncology, 1999
- Detection of t(2;5) in Anaplastic Large Cell LymphomaThe American Journal of Surgical Pathology, 1999
- ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological SpectrumThe American Journal of Pathology, 1998
- Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. ClassificationAnnals of Oncology, 1998
- Anaplastic Large Cell Lymphoma: A Distinct Molecular Pathologic EntityThe American Journal of Surgical Pathology, 1997
- Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.Journal of Clinical Oncology, 1997
- 16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell LymphomaLeukemia & Lymphoma, 1995
- Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies.Journal of Clinical Oncology, 1994
- Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.Journal of Clinical Pathology, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993